Retrospective Study
Copyright ©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 628-640
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Table 6 Characteristics of the study population according to use of ribavirin
Number (%)
CharacteristicRBV-containing DAA regimens (n = 68)Non-RBV containing DAA regimens (n = 38)P value
Age ≥ 60 yr38 (58)26 (70)0.2
Male51 (75)24 (63)0.3
Female17 (25)14 (37)
White37 (54)19 (50)0.8
Black15 (22)7 (18)
Hispanic13 (19)10 (26)
Asian3 (4)2 (5)
Diabetes Mellitus45 (66)28 (74)0.5
CKD22 (32)21 (55)0.02
eGFR < 30 mL/min/1.73 m21 (2)8 (21)0.001
Cirrhosis4 (8)5 (16)0.3
mean (± SD) creatinine level, mg/dL1.2 ± 1.01.9 ± 1.80.02
mean (± SD) hemoglobin level, g/dL14.0 ± 1.712.0 ± 2.00.0001
mean (± SD) MELD-Na score11 ± 413 ± 60.01
SVR1265 (95.5)35 (92.1)0.7